Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) EPS (Basic) (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of EPS (Basic) data on record, last reported at -$0.75 in Q3 2025.

  • For Q3 2025, EPS (Basic) fell 1406.72% year-over-year to -$0.75; the TTM value through Sep 2025 reached -$0.75, up 95.29%, while the annual FY2024 figure was -$5.65, 65.88% up from the prior year.
  • EPS (Basic) reached -$0.75 in Q3 2025 per COEP's latest filing, up from -$1.28 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.5 in Q1 2021 and bottomed at -$15.8 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$1.24, with a median of -$0.13 recorded in 2023.
  • Peak YoY movement for EPS (Basic): soared 121.05% in 2022, then plummeted 7574.94% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.13 in 2021, then plummeted by 58.36% to -$0.21 in 2022, then tumbled by 7574.94% to -$15.8 in 2023, then surged by 65.57% to -$5.44 in 2024, then surged by 86.15% to -$0.75 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.75 in Q3 2025, -$1.28 in Q2 2025, and -$1.11 in Q1 2025.